Pfizer Corporation

Thomas K Schaaf

Jasjit S Bindra

Hans-Jurgen E Hess

Michael Ross Johnson

James F Eggler

Elias James Corey

Leonard J Czuba

11-Desoxy-16-aryloxy-.omega.-tetranorprostaglandins are disclosed. The novel prostaglandins of this invention have been found to have activity profiles comparable to the parent prostaglandins but they exhibit a greater tissue specificity of action.

11-Desoxy-16-aryloxy-.omega.-tetranorprostaglandins

15-Substituted-.omega.-pentanorprostaglandin C-1 tetrazoles, imides and sulfonimides. Their use as anti-secretory agents or as agents for the control of fertility.

15-Substituted-.omega.-pentanorprostaglandin derivatives

2-Descarboxy-2-(tetrazol-5-yl)-16,16-dimethyl-17-(

The synthetic prostaglandin derivatives have a C-1 alkylsulfonylcarboxamide group, a trans C-2, C-3 double bond or cis C-4, C-5 double bond and a C-16 aryloxy group and are antiulcer or antifertility agents.

Sulfonyl prostaglandin carboxamide derivatives

The 15 aryl substituted-.omega.-pentanorprostaglandins and various intermediates empolyed in their preparation. The novel prostaglandins of this invention have been found to have activity profiles comparable to the parent prostaglandins, but exhibit a greater tissue specificity of action.

15-Substituted-omega-pentanorprostaglandins

Synthetic prostaglandin E compounds having carboxylic acid, ester, tetrazol, sulfonamide or imide substitutions at C-1, a methanesulfonamido group replacing the C-15 hydroxy and an aryloxy group at C-16 are disclosed. They exhibit antisecretory biological activity.

15-Sulfonamidoprostaglandin derivatives

A new synthesis of key prostaglandin precursors and intermediates employed in their preparation. The novel synthetic sequence of this invention is shorter and more efficient than those previously employed to prepare to key intermediate.

Intermediates for synthesis of precursors for prostaglandins

11-DESOXY-15-SUBSTITUTED-.omega.-PENTANORPROSTAGLANDINS AND VARIOUS INTERMEDIATES EMPLOYED IN THEIR PREPARATION. The novel prostaglandins of this invention have been found to have activity profiles comparable to the parent prostaglandins, but exhibit a greater tissue specificity of action.

11-Desoxy-15-substituted-.omega.-pentanor prostaglandins

The 15-substituted-.omega.-pentanorprostaglandins and various intermediates employed in their preparation. The novel prostaglandins of this invention have been found to have activity profiles comparable to the parent prostaglandins, but exhibit a greater tissue specificity of action.

Growing community of inventors

Old Lyme, CT, United States of America

Thomas K Schaaf